NCT04883619View on ClinicalTrials.gov

A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 15, 2026

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
Lupus Nephritis
Interventions
OTHER

Placebo

Placebo will be administered intravenously.

DRUG

Nipocalimab

Nipocalimab dose 1 and dose 2 will be administered intravenously.

DRUG

Standard-of-care treatment

Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY